NCT04511650View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

February 26, 2021

Study Completion Date

February 26, 2021

Conditions
COVID-19Acute Respiratory Distress Syndrome (ARDS)
Interventions
DRUG

Razuprotafib Subcutaneous Solution

Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.

DRUG

Placebo Subcutaneous Solution

Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days

Trial Locations (7)

20007

MedStar Georgetown University Hospital, Washington D.C.

45219

University of Cincinnati, Cincinnati

55455

University of Minnesota, Minneapolis

83404

Snake River Research, Idaho Falls

90033

University of Southern California, Los Angeles

92868

University of California- Irvine Medical Center, Orange

02905

Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY

NCT04511650 - Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 | Biotech Hunter | Biotech Hunter